Several studies have reported the differential up-modulation of genes C1QA (encoding the C1q complement protein, chain A) (34, 35), CD163 (34, 35), GILZ (32, 35, 36), MERTK (encoding the MER Proto-Oncogene Tyrosine Kinase, also used as a marker in the abovementioned clinical trial for Crohn's disease) (12, 26, 35) and ZBTB16 (encoding zinc finger and BTB domain containing protein 16) (34, 35) in dexa-tolDC, thus making them the most relevant candidate biomarkers for this specific protocol. Here, ZBTB16 is linked to Crohn disease.